



# REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

**propofol**



<b>Effective Date:</b> Dec 2011	CLASSIFICATION <b>Intravenous anesthetic</b>	OTHER NAMES <b>Diprivan</b>	PAGE 1 of 3
<b>Revised Date:</b> June 2024			

**ADMINISTRATION POLICY:**

- IV Infusion – May be administered by a nurse experienced in ED/CARDIAC ROOM/ICU/OR/PACU
- IV Bolus – May be administered by a nurse under direct supervision of prescriber

**RECONSTITUTION/DILUTION/ADMINISTRATION:**

**Available as:** 10 mg/mL; 20 mL, 50 mL and 100 mL vials. **SHAKE BEFORE USE. DO NOT FILTER.**

**IV Bolus:** Administer undiluted over 3 to 5 minutes

**IV Infusion: Pump Library:** Administer undiluted using vent. Change tubing every 12 hours.

**NOTE: MAY BE ORDERED IN EITHER OF THE FOLLOWING DOSE RATES. CHOOSE APPROPRIATELY.**

**Propofol mcg/kg/min**

Drug Library	Dose Rate	Short Name	Care Unit
Yes	mcg/kg/min	propofol,	Critical Care
Drug	Diluent	Final Volume (VTBI)	Final Concentration
500 or 1000 mg	50 or 100 mL premixed	50 or 100 mL	10 mg/mL
Clinical Advisory: High Alert			
Soft Low Dose Limit: 1 mcg/kg/min		Soft High Dose Limit: 100 mcg/kg/min	

**Propofol mg/kg/h**

Drug Library	Dose Rate	Short Name	Care Unit
Yes	mg/kg/h	propofol	Critical Care
Drug	Diluent	Final Volume (VTBI)	Final Concentration
500 or 1000 mg	50 or 100 mL premixed	50 or 100 mL	10 mg/mL
Clinical Advisory: High Alert			
Soft Low Dose Limit: 0.3 mg/kg/h		Soft High Dose Limit: 5 mg/kg/h	

**DOSAGE:**

- IV bolus:** 0.1 to 2 mg/kg
- IV infusion:** 5 to 60 mcg/kg/min. Adjust dose after 5 minutes in increments of 5 to 10 mcg/kg/min.  
**OR**  
0.3 mg/kg/hour. Increased by 0.3 to 0.6 mg/kg/hour every 5 to 10 minutes.  
Maintenance: 0.3 to 3 mg/kg/hour
- Maximum dose:** \*Note: higher doses up to 200 mcg/kg/min in the OR  
IV bolus (for procedural sedation): 200 mg
- Maximum rate:** IV bolus: Over 3 minutes  
IV continuous: 80 mcg/kg/min **OR** 5mg/kg/hr
- Maximum concentration:** 10 mg/mL



## REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

**propofol**



<b>Effective Date:</b> Dec 2011	CLASSIFICATION	OTHER NAMES	PAGE
<b>Revised Date:</b> June 2024	<b>Intravenous anesthetic</b>	<b>Diprivan</b>	2 of 3

### STABILITY/COMPATIBILITY:

**Stability of reconstituted solution:** 12 hours at room temperature, after initial use of vial.  
**DISCARD ANY UNUSED PORTIONS**

**Compatibility:** Compatible with D5W, Lactated Ringer

### PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Respiratory depression, apnea, hypoxia (see note under dosage)
- Hypotension is the major cardiovascular effect of propofol especially if patient is hypovolemic or if bolus is used. Use with caution in patients who are hemodynamically unstable, hypovolemic, or have abnormally low vascular tone i.e. sepsis.
- Bradycardia, local pain, nausea and vomiting
- Patients who develop hypertriglyceridemia (i.e. greater than 500 mg/dL) are at risk of developing pancreatitis. Serum triglyceride levels should be obtained prior to initiation of therapy and every 3 to 7 days thereafter. Monitoring of serum triglycerides should especially be considered with therapy >48 hours with doses exceeding 50 mcg/kg/minute (Devlin 2005). An alternative sedative agent should be employed if significant hypertriglyceridemia occurs. Use with caution in patients with preexisting hyperlipidemia as evidenced by increased serum triglyceride levels or serum turbidity.
- **Propofol related infusion syndrome:** Metabolic acidosis, rhabdomyolysis and cardiovascular collapse reported with doses **greater than 5 mg/kg/hour** for durations of **greater than 48 hours**. **In the event of this syndrome occurring, contact the physician immediately.**
- Do not mix with ketamine in the same syringe
- May turn urine green

### ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Sedation and respiratory function is monitored according to the Procedural Sedation Guideline
- Continuous Cardiac monitoring, continuous SpO<sub>2</sub> and non-invasive monitoring (exception palliative care).
- Flush tubing slowly after use. This drug **MUST** be drawn up in a syringe **JUST PRIOR** to use.
- There is no reversal agent available for propofol
- Drug is suspended in a fatty emulsion vehicle and contains 10 % fat (1.1 kcal/mL). Use with caution in patients with lipid metabolism disorders (e.g.: pancreatitis). Consider this source of fat in patients on enteral or parenteral nutrition.
- Propofol is preservative free and supports microbial growth; aseptic technique is mandatory
- Contraindicated in patients with propofol, soybean, egg, or glycerol allergies
- If propofol is administered in combination with other CNS active drugs, reduce dosage accordingly due to the increased risk of respiratory depression, apnea and hypoxia
- Elderly patients: Dose reduction of 50% may be required, hypovolemic



# REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME  
**propofol**



Effective Date: Dec 2011

Revised Date: June 2024

CLASSIFICATION  
**Intravenous anesthetic**

OTHER NAMES  
**Diprivan**


PAGE

3 of 3

## INSTRUCTION GUIDE

Using the two types of hangers provided with  
PMS-PROPOFOL 10mg/mL (formats of 100mL and 50mL)

### Hanger Type 1



### Hanger Type 2

